Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VERU

Veru Inc

Dec 22 • 04:00PM ET

2.29

-0.03 -1.29 %

Healthcare • Biotechnology • USA • NASD

Peers: TNXP TXMD ASRT CDTX HRTX DSGN CRBP TGTX MNKD XERS

| Held by: VTI VXF MSSM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.27	Insider Own	12.84%	Shs Outstand	14.65M	Perf Week	-4.18%
Market Cap	36.76M	Forward P/E	-	EPS next Y	-1.52	Insider Trans	0.00%	Shs Float	13.99M	Perf Month	2.69%
Enterprise Value	21.56M	PEG	-	EPS next Q	-0.32	Inst Own	22.00%	Short Float	5.11%	Perf Quarter	-32.05%
Income	-18.67M	P/S	-	EPS this Y	12.02%	Inst Trans	-5.25%	Short Ratio	4.00	Perf Half Y	-65.71%
Sales	0.00M	P/B	1.83	EPS next Y	-11.53%	ROA	-34.60%	Short Interest	0.71M	Perf YTD	-64.80%
Book/sh	1.25	P/C	2.01	EPS next 5Y	3.37%	ROE	-61.92%	52W High	14.20 -83.87%	Perf Year	-65.82%
Cash/sh	1.14	P/FCF	-	EPS past 3/5Y	50.51% 14.86%	ROIC	-90.24%	52W Low	2.11 8.53%	Perf 3Y	-95.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.26% 7.43%	Perf 5Y	-97.64%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	55.10%	Oper. Margin	-	ATR (14)	0.20	Perf 10Y	-83.76%
Dividend Ex-Date	Apr 28, 2014	Quick Ratio	2.43	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	38.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	115.27%	SMA20	-5.63%	Beta	-1.42	Target Price	25.00
Payout	-	Debt/Eq	0.17	Sales Q/Q	-100.00%	SMA50	-20.75%	Rel Volume	1.66	Prev Close	2.32
Employees	20	LT Debt/Eq	0.13	Earnings	Dec 17 BMO	SMA200	-48.09%	Avg Volume	178.89K	Price	2.29
IPO	Jul 19, 1990	Option/Short	Yes / Yes	EPS/Sales Surpr.	113.70% -	Trades		Volume	292,174	Change	-1.29%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Initiated	Canaccord Genuity	Buy	$25
May-14-24	Initiated	B. Riley Securities	Buy	$5
Mar-28-24	Initiated	Raymond James	Outperform	$3
Jun-07-23	Upgrade	Jefferies	Underperform → Hold	$1
Apr-13-21	Initiated	Jefferies	Buy	$19
Feb-09-21	Reiterated	H.C. Wainwright	Buy	$12 → $17
Jan-21-20	Reiterated	H.C. Wainwright	Buy	$4.50 → $6
Mar-20-19	Initiated	Oppenheimer	Outperform	$5
Jul-03-18	Initiated	Maxim Group	Buy

Dec-17-25 02:00PM	Veru Inc (VERU) Q4 2025 Earnings Call Highlights: Strategic Shifts and Financial Challenges (GuruFocus.com) -8.61%
06:30AM	Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress (GlobeNewswire)
Dec-10-25 08:30AM	Veru to Report Fiscal Year 2025 Financial Results on December 17th (GlobeNewswire)
Dec-04-25 08:30AM	Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop (GlobeNewswire)
Oct-31-25 08:30AM	Veru to Present Two Abstracts at ObesityWeek 2025 (GlobeNewswire)
08:00AM	Loading…
Oct-30-25 08:00AM	Veru Announces Pricing of $25 Million Public Offering (GlobeNewswire) -14.00%
Oct-29-25 04:01PM	Veru Announces Proposed Public Offering (GlobeNewswire)
Oct-02-25 03:06PM	Starting first phase of long-term small cap outperformance relative to large: Palisade's Dan Veru (CNBC TV)
Sep-27-25 08:40AM	Onconetix announces financing through private placement, debt settlement (TipRanks)
Sep-23-25 08:30AM	Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity (GlobeNewswire) -5.60%
Aug-15-25 09:20AM	Veru Announces Novel Modified-Release Oral Formulation for Enobosarm (Zacks)
Aug-12-25 06:30AM	Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress (GlobeNewswire) -11.70%
Aug-11-25 04:01PM	Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Verus Enobosarm, Utilizing Laxxons SPID®-Technology (Business Wire)
09:30AM	Veru Inc (VERU) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
08:30AM	Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study (GlobeNewswire)
08:30AM	Loading…
Aug-06-25 08:30AM	Veru Announces Reverse Stock Split (GlobeNewswire) -18.72%
Aug-05-25 08:30AM	Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th (GlobeNewswire) -6.39%
Jul-22-25 08:30AM	Veru to Participate in the 2025 BTIG Virtual Biotech Conference (GlobeNewswire)
Jun-24-25 08:30AM	Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation (GlobeNewswire) +7.73%
Jun-11-25 08:30AM	Veru to Participate in the Virtual BTIG Obesity Health Forum (GlobeNewswire)
May-28-25 07:48AM	Muscle-sparing obesity drug safe for Phase 3 trial, Veru says (BioPharma Dive)
06:30AM	Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone (GlobeNewswire)
May-09-25 03:08AM	Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ... (GuruFocus.com)
May-08-25 09:25AM	Veru Participates in a Virtual Investor KOL Connect Segment (GlobeNewswire)
06:30AM	Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress (GlobeNewswire)
May-07-25 02:26PM	Veru Q2 2025 Earnings Preview (Seeking Alpha)
11:39AM	Veru Inc (VERU) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-01-25 08:30AM	Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8 (GlobeNewswire)
Apr-16-25 08:30AM	Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit (GlobeNewswire)
Mar-31-25 08:30AM	Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
09:55AM	Loading…
Mar-12-25 09:55AM	Here's Why Veru (VERU) Looks Ripe for Bottom Fishing (Zacks)
Mar-06-25 09:35AM	Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround (Zacks)
Feb-14-25 07:12AM	Veru: Discussions on tariffs are negotiation means to an end (CNBC TV)
02:08AM	Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ... (GuruFocus.com)
Feb-13-25 06:30AM	Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress (GlobeNewswire)
Feb-12-25 07:51AM	Veru Inc (VERU) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-06-25 08:30AM	Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025 (GlobeNewswire)
Feb-04-25 08:30AM	Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -6.04%
Jan-27-25 07:00AM	Muscle-building drug improves body composition in obesity trial, Veru says (BioPharma Dive) -47.51%
06:30AM	Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction (GlobeNewswire)
Jan-23-25 12:00PM	What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now? (Zacks) +23.08%
Dec-31-24 11:29AM	Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline (Benzinga)
08:30AM	Veru Announces the Sale of the FC2 Female Condom (Internal Condom) Business (GlobeNewswire)
Dec-16-24 07:00PM	Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +8.68% -9.18%
Nov-26-24 08:30AM	Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, and Wasting Disorders (GlobeNewswire) +8.00%
08:30AM	Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders (GlobeNewswire)
Nov-08-24 08:02AM	Veru: With the new administration, the Fed may pause to see how policies will impact inflation (CNBC TV)
Nov-05-24 08:30AM	Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek (GlobeNewswire)
Oct-21-24 08:30AM	Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss (GlobeNewswire)
Oct-16-24 08:30AM	Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress (GlobeNewswire)
Oct-09-24 05:27PM	Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ... (GuruFocus.com) +9.42% -9.36%
Sep-11-24 08:30AM	Veru to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-16-24 08:09AM	Veru: The biggest risk for the markets is to focus on just one data point (CNBC TV)
Aug-08-24 07:45AM	Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.34%
06:30AM	Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results (GlobeNewswire)
Aug-06-24 08:45AM	Rapid Advancements of Innovative Antiviral COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market (GlobeNewswire)
Aug-01-24 08:30AM	Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024 (GlobeNewswire) -5.03%
Jul-29-24 08:30AM	Veru to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-02-24 08:30AM	Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism (GlobeNewswire) +8.52%
Jun-26-24 07:53AM	VERU Stock Earnings: Veru Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
Jun-24-24 08:30AM	Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire) +9.04%
Jun-18-24 04:05PM	Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024 (GlobeNewswire)
Jun-17-24 04:45PM	Veru Reminds Shareholders to Vote in Advance of Tomorrows Deadline for 2024 Annual Meeting of Shareholders (GlobeNewswire)
Jun-10-24 08:30AM	Veru to Present at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-22-24 08:30AM	Veru to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-24 08:30AM	Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss (GlobeNewswire)
May-14-24 08:30AM	Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week (GlobeNewswire) +10.53%
May-13-24 10:43AM	Fathom Holdings Inc. (NASDAQ:FTHM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 03:01AM	Veru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial Recovery (GuruFocus.com)
May-08-24 08:39AM	Veru Inc. (VERU) Fiscal 2024 Q2 Earnings: Clinical Advances Amid Financial Strains (GuruFocus.com) -12.27%
06:30AM	Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program (GlobeNewswire)
May-02-24 08:30AM	Veru to Present at the GLP-1 Based Therapeutics Summit (GlobeNewswire) +10.07%
May-01-24 08:30AM	Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024 (GlobeNewswire) +10.37%
Apr-30-24 09:55AM	Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) +8.00%
08:30AM	Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss (GlobeNewswire)
Apr-25-24 08:30AM	Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 (GlobeNewswire) -8.33%
Apr-17-24 12:00PM	What Makes Veru (VERU) a New Buy Stock (Zacks) -7.57%
Apr-01-24 04:05PM	Veru Announces Date of 2024 Annual Meeting of Shareholders (GlobeNewswire) +8.56%
Mar-22-24 04:05PM	Veru Reschedules Annual Meeting of Shareholders (GlobeNewswire) +8.79%
Mar-15-24 01:46PM	Fathom Holdings Inc. (NASDAQ:FTHM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 07:30AM	Some of the market headwinds will soon become tailwinds, says Dan Veru (CNBC TV)
Mar-12-24 08:00AM	Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss (GlobeNewswire)
Feb-27-24 07:15PM	Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q (GlobeNewswire) +17.45%
Feb-20-24 08:30AM	Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss (GlobeNewswire)
Feb-13-24 09:35AM	After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU) (Zacks)
Feb-09-24 10:46AM	Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript (Insider Monkey) -7.61%
Feb-08-24 10:19PM	Q1 2024 Veru Inc Earnings Call (Thomson Reuters StreetEvents) -6.57%
10:14AM	Veru needs additional cash for fresh trial of respiratory distress drug (FierceBiotech.com)
06:30AM	Veru Reports Fiscal 2024 First Quarter Financial Highlights (GlobeNewswire)
Feb-06-24 08:30AM	Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs (GlobeNewswire) -10.06%
Feb-01-24 10:00AM	Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Jan-31-24 08:30AM	Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-25-24 08:30AM	Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024 (GlobeNewswire)
Jan-08-24 08:30AM	Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss (GlobeNewswire)
07:37AM	Movement in bond yields will be the story for 2024, says Dan Veru (CNBC TV)
Dec-19-23 08:30AM	Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs (GlobeNewswire) +5.69%
Dec-14-23 09:00AM	Veru Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -8.94%
Dec-13-23 04:01PM	Veru Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Dec-07-23 06:00AM	Cancer Cachexia Market revenue to reach USD 4.5 Billion by 2036, says Research Nester (GlobeNewswire)
Oct-05-23 07:18AM	Veru: Markets are finally waking up to the reality of higher rates for longer (CNBC TV)

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. The company was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1971 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rankowitz Michael L	Director	Feb 18 '25	Buy	0.55	95,279	52,432	195,279	Feb 20 10:00 AM
Rankowitz Michael L	Director	Feb 19 '25	Buy	0.58	54,721	31,919	250,000	Feb 20 10:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VERU

Veru Inc

Upgrade your FINVIZ experience